A Confirmatory Study of AMG 162 (Denosumab) in Patients With Rheumatoid Arthritis on DMARDs Treatment (Phase III)

Trial Profile

A Confirmatory Study of AMG 162 (Denosumab) in Patients With Rheumatoid Arthritis on DMARDs Treatment (Phase III)

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Apr 2018

At a glance

  • Drugs Denosumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms DESIRABLE
  • Sponsors Daiichi Sankyo Inc
  • Most Recent Events

    • 08 Nov 2017 Results of sub-group analysis (n=909) assessing the effect of denosumab upon progression of the joint destruction in rheumatoid arthritis patients using pooled data from two trials (DRIVE and DESIRABLE), presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
    • 05 Oct 2017 Status changed from active, no longer recruiting to completed.
    • 17 Jun 2017 Primary endpoint has been met. (Change from baseline in Total Sharp Score (TSS) at month 12), as reported in an abstract presented at the 18th Annual Congress of the European League Against Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top